BridgeBio Pharma Inc at Goldman Sachs Global Healthcare Conference Transcript
Good afternoon. We'll continue with the next session. I'm Paul Choi, and I cover the SMid Cap Biotechnology sector here at the firm. And it's my pleasure to welcome BridgeBio for this session. From management joining us is Founder and CEO, Neil Kumar. What we'll do is Q&A. If any audience members along the way have any questions for Neil, please feel free to raise your hand, and we'll try and get a mic to you. But maybe before we start with Q&A, Neil, maybe if you want to provide some any high-level comments that you think are of interest. Otherwise, we can just go into Q&A.
Yes, sure. Happy to. First of all, thanks, everyone, for the time. I think our strategy a bit large over the next 18 months or so is informed by 2 inputs, really, number 1 is our continued belief in our late-stage pipeline of Phase II or Phase III assets in $1 billion-plus markets. And we can talk about those, but those are five
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |